ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma

TOP - November 2021 Vol 14, No 7 - Neuroblastoma

ALK inhibitor therapy achieved “remarkable” response rates in a small study of patients with ALK-positive adult-onset neuroblastoma. Some patients who did not respond to initial treatment with 1 ALK inhibitor had a subsequent response to lorlatinib (Lorbrena), which had the best showing among ALK inhibitors evaluated in this setting. The results of this retrospective study were presented at the American Society of Clinical Oncology 2021 virtual annual meeting.

“Adult-onset neuroblastoma is a rare cancer that is challenging to treat, because patients cannot tolerate the chemotherapy regimens used on children. ALK is an appealing drug target and use of an ALK inhibitor can be a well-tolerated option for treatment of these patients, improving response and time to disease progression,” said lead investigator Jessica Stiefel, MD, Third Year Pediatric Hematology/Oncology Fellow, Memorial Sloan Kettering Cancer Center, New York City.

“Our experience shows that development of resistance to 1 ALK inhibitor does not preclude use of other agents within the same drug class. Overall, ALK-targeted therapy appears to be a safe and effective option for adult-onset neuroblastoma and should be considered when making this diagnosis,” she added.

Neuroblastoma typically occurs in children, with a median onset at age 5, and is usually treated with chemotherapy and radiation. Adult-onset neuroblastoma is a rare and biologically distinct cancer compared with childhood neuroblastoma.

“Adult-onset neuroblastoma is metastatic, chemotherapy-resistant, and almost invariably fatal,” Dr Stiefel explained. “The presence of ALK mutations in adult-onset neuroblastoma provides an opportunity for targeted therapy for a disease that is otherwise very challenging to treat.”

Study Details

Dr Stiefel presented data from a retrospective review based on 23 adult patients with adult-onset neuroblastoma who were genetically sequenced at Memorial Sloan Kettering Cancer Center between 2014 and 2020. Fourteen (61%) patients were found to harbor ALK somatic mutations. Of these 14, 7 were treated with 1 or more FDA-approved ALK inhibitors. Her presentation focused on these 7 patients.

One patient was diagnosed with the disease at age 12 years, and the other 6 at ages ranging from 28 to 68 years. Patients were treated with 1 to 4 previous regimens. Most had measurable disease at treatment initiation and had metastatic disease at diagnosis. Previous multimodality treatment included surgery, chemotherapy, and radiation.

Overall, treatment with ALK inhibitors was well-tolerated. Dizziness, drowsiness, and hallucinations were reported in 1 patient each, and these effects resolved when treatment was stopped. Grade 1 nausea and vomiting were reported in 6 patients. Treatment discontinuations were reported in 4 patients taking crizotinib (Xalkori) and alectinib (Alecensa).

“Lorlatinib was the best tolerated ALK inhibitor,” Dr Stiefel said. “No patient receiving lorlatinib required discontinuation due to adverse events, and 1 required a dose reduction.”

All 7 patients had an initial response to an ALK inhibitor, but 6 discontinued due to progressive disease or adverse events (3 each). Median time to progression was 15.5 months. Median overall survival was 46.5 months (range, 17-74 months).

Four patients treated with more than 1 ALK inhibitor continued to be in response and were started on lorlatinib therapy after disease progression on other ALK inhibitors. Two patients had stable disease.

Related Items
Multicancer Early Detection Blood Test May Change Cancer Screening Paradigms
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Determination Trial Confirms Importance of Individualizing Therapy for Newly Diagnosed Multiple Myeloma
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Multiple Myeloma
Researchers Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Promising New Approach to Treating Patients with Desmoid Tumors
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in ESMO
Radiation Therapy May Be Omitted for Some Older Women with Luminal A Breast Cancer
Patricia Stewart
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in Breast Cancer
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Prostate Cancer
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in COVID-19 & Cancer
Neoadjuvant Chemoimmunotherapy Shows Promise in Advanced Ovarian Cancer
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Ovarian Cancer
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Last modified: November 12, 2021